glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Vitamin B12 is important for breaking down fatty acids and amino acids
Those considering BPC-157 should understand they are using an experimental compound with unknown long-term effects, sourced from an unregulated market where product quality and purity cannot be guaranteed
What is the recommended injection timing for Ipamorelin